In this retrospective study of a cohort of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) patients treated with eculizumab, the authors reported efficacy with decreasing relapse rate, magnetic resonance imaging changes, and disability outcomes, but cautioned about the risk of serious infections.
ABSTRACT & COMMENTARY
Eculizumab for Treating Aquaporin-4 Antibody-Positive NMOSD
November 1, 2024